

REC Ref.	IRAS No.	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
18/NW/0107	236834	PHIL evaluation in the endovascular treatment of intracranial cerebral ArterioVenous Malformation	Yes, target number agreed	6	6	Yes a date was agreed	31/08/2019	0	26/10/2018	0	Withdrawn by Sponsor
18/LO/0666	242700	Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).	Yes, a range was agreed	2	2	Yes a date was agreed	01/07/2020	2	22/10/2018	2	Recruitment finished
17/LO/0380	218003	PET-LONGITUDINAL SUBSTUDY ASSOCIATED WITH: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER'S DISEASE	Yes, target number agreed	1	1	Yes a date was agreed	19/06/2018	1	19/06/2018	1	Recruitment finished
17/LO/1695	234684	A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Medicated Gene Transfer of Human Factor VIII in Haemophilia A Patients with Residual FVIII Levels ≥ 1 IU/dl Receiving Prophylactic FVIII Infusions.	Yes, target number agreed	1	2	Yes a date was agreed	01/06/2018	0	01/06/2018	0	Recruitment finished
17/SC/0394	229032	An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib.	Yes, target number agreed	3	3	Yes a date was agreed	31/12/2018	4	12/12/2018	4	Recruitment finished
17/EE/0026	220207	A Prospective, Randomized, Controlled, Multi-Center Clinical Study of the ACRYSOF IQ Extended Depth of Focus (EDF) IOL	Yes, target number agreed	20	20	Yes a date was agreed	01/10/2018	11	30/07/2018	11	Recruitment finished
17/EM/0236	221138	Dose finding phase IIb study of Bavisant to evaluate its safety and efficacy in treatment of excessive daytime sleepiness (EDS) in Parkinson's Disease (PD).	Yes, target number agreed	4	4	No a date is not available / was not agreed		3	31/07/2018	3	Recruitment finished
17/EE/0177	220722	A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM).	Yes, target number agreed	3	3	Yes a date was agreed	01/06/2020	7	26/09/2018	7	Recruitment finished
17/EM/0154	222912	A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects with Parkinson's Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLEd)	Yes, target number agreed	4	4	Yes a date was agreed	01/12/2018	5	01/12/2018	5	Recruitment finished
17/NE/0165	217768	AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS	Yes, target number agreed	4	4	Yes a date was agreed	31/05/2018	4	31/05/2018	4	Recruitment finished
17/SC/0122	224090	AR101 Trial in Europe Measuring Oral Immunotherapy Success in Peanut Allergic Children	Yes, target number agreed	12	12	Yes a date was agreed	01/12/2018	12	01/12/2018	15	Recruitment finished

17/LO/0783	225826	A Multicenter, Parallel-Group, Randomized, Cross-Over Trial to Compare the Efficacy of LUMINITY® and SonoVue® in the Evaluation of Left Ventricular Endocardial Border Definition	Yes, target number agreed	4	4	Yes a date was agreed	14/05/2018	0	21/03/2018	0	Withdrawn by Sponsor
17/EM/0116	222773	A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson's Disease Experiencing End of Dose "Wearing-Off"	Yes, target number agreed	4	4	Yes a date was agreed	01/06/2018	0	30/06/2018	0	Recruitment finished
17/NW/0180	220257	A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy.	Yes, target number agreed	2	2	No a date is not available / was not agreed		1	08/08/2018	1	Recruitment finished
17/NW/0175	222859	A Phase 1b Open-Label, Dose Escalation Study of PRTX-100 in Adult patients with Persistent/Chronic Immune Thrombocytopenia	Yes, target number agreed	1	1	Yes a date was agreed	15/11/2017	2	17/05/2018	2	Recruitment finished
17/LO/0304	222475	A double-blind, randomised, placebo-controlled, parallel-group, phase 2, dose-ranging trial to evaluate the efficacy, safety and tolerability of oral Litoxetine 10mg, 20mg and 40mg twice daily (BID) versus placebo in women with mixed urinary continence	Yes, target number agreed	10	12	Yes a date was agreed	31/10/2018	0	30/05/2018	0	Withdrawn by Sponsor
17/EE/0081	219405	An open label, single arm pilot study of OncoSilâ„¸, administered to study participants with unresectable locally advanced pancreatic adenocarcinoma, given in combination with FOLFIRINOX or gemcitabine+nab-paclitaxel chemotherapies.	Yes, target number agreed	2	2	Yes a date was agreed	01/06/2020	6	26/06/2018	6	Recruitment finished
17/EE/0079	220827	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprine	Yes, target number agreed	1	1	Yes a date was agreed	31/12/2018	1	31/12/2018	1	Recruitment finished
17/LO/0089	219229	A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic HCV Infection Who are on Dialysis for End Stage Renal Disease	Yes, target number agreed	3	3	Yes a date was agreed	31/01/2018	6	31/01/2018	6	Recruitment finished
16/LO/2148	219354	A Multi-Centre, Open Label, Phase IIb Study, Evaluating the Safety, Tolerability and Efficacy of Targeted Intraprostatic Administration of PRX302 to Treat Men with Histologically Proven, Clinically Significant, Localised, Low- to Intermediate-Risk Prostate Cancer that is Associated with an MRI Lesion	Yes, target number agreed	4	4	Yes a date was agreed	01/01/2018	8	07/01/2018	8	Recruitment finished
17/EM/0005	215706	A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects with Chronic Heart Failure with Reduced Ejection Fraction	Yes, target number agreed	15	15	Yes a date was agreed	05/01/2020	0	29/01/2018	0	Withdrawn by Sponsor
15/NE/0389	194347	Phase 1 study to assess Single Doses of ABY-035 in Healthy Subjects and Psoriasis Patients	Yes, target number agreed	3	3	Yes a date was agreed	01/02/2018	3	01/02/2018	3	Recruitment finished
16/LO/0542	201528	An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)	Yes, target number agreed	04/01/1900	04/01/1900	Yes a date was agreed	31/01/2017	2	01/05/2018	2	Recruitment finished
17/LO/0052	212454	Evaluation of Uterine Patency following Sonography-guided Transcervical Ablation of Fibroids	Yes, target number agreed	10/01/1900	10/01/1900	Yes a date was agreed	01/11/2018	9	28/09/2018	9	Recruitment finished
16/LO/1244	200385	A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy	Yes, target number agreed	03/01/1900	03/01/1900	Yes a date was agreed	12/11/2018	3	12/11/2018	3	Recruitment finished

16/EM/0376	211430	The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by 14 or 40-Week Extension Periods	Yes, target number agreed	03/01/1900	04/01/1900	No a date is not available / was not agreed		0	15/02/2018	0	Recruitment finished
14/LO/0344	140294	A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of Talazoparib (BMN 673) versus Physician's Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Who Have Received Prior Chemotherapy Regimens for Metastatic Disease	Yes, target number agreed	01/01/1900	01/01/1900	Yes a date was agreed	20/04/2018	2	20/04/2018	2	Recruitment finished
16/LO/0675	147355	A PHASE 2, INTERNATIONAL, MULTICENTER, RANDOMIZED, OPENLABEL, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) ALONE AND IN COM+H768BINATION WITH DURVALUMAB (MEDI4736) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTION OR DECITABINE	Yes, target number agreed	03/01/1900	03/01/1900	Yes a date was agreed	31/10/2019	0	03/07/2018	0	Withdrawn by Sponsor
16/YH/0083	192397	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma.	Yes, target number agreed	20/01/1900	20/01/1900			24	26/11/2018	24	Recruitment finished
16/LO/0118	191634	Valiant Evo International Clinical Trial	Yes, target number agreed	04/01/1900	04/01/1900	Yes a date was agreed	30/07/2018	5	10/05/2018	5	Recruitment finished
17/WS/0030	191416	A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	Yes, target number agreed	02/01/1900	02/01/1900	Yes a date was agreed		5	03/03/2018	5	Recruitment finished
15/WM/0453	172946	A Open Label, Randomised, Pre-surgical, Pharmacodynamics Study to Compare the Biological Effects of AZD9496 versus Fulvestrant in Postmenopausal Women with estrogen receptor positive HER-2 negative Primary Breast Cancer	Yes, target number agreed	05/01/1900	05/01/1900	No a date is not available / was not agreed		0	30/11/2018	0	Recruitment finished
16/EM/0032	197351	A three-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wt, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease	Yes, target number agreed	03/01/1900	03/01/1900	Yes a date was agreed	26/08/2016	3	03/03/2018	3	Recruitment finished
16/YH/0081	186580	A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Proliferative Lupus Nephritis.	Yes, target number agreed	01/01/1900	01/01/1900	Yes a date was agreed	24/04/2018	0	24/04/2018	0	Recruitment finished
16/NE/0023	190035	A Phase III, Multi-centre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study with Open-Label Extension of Crenezumab in Patients with Prodromal-to-Mild Alzheimer's Disease	Yes, target number agreed	08/01/1900	08/01/1900	Yes a date was agreed	01/08/2018	8	01/08/2018	8	Recruitment finished
15/YH/0434	185622	Dose Optimization Study of Idelalisib in Follicular Lymphoma and Small Lymphocytic Lymphoma.	Yes, target number agreed	02/01/1900	02/01/1900	Yes a date was agreed	01/06/2019	0	01/08/2018	0	Withdrawn by Host
16/LO/0351	190075	A double blind, randomized placebo controlled crossover multiple dose study of LJM452 to assess safety, tolerability and efficacy in patients with primary bile acid diarrhea (pBAD)	Yes, target number agreed	07/01/1900	07/01/1900	Yes a date was agreed		9	07/02/2018	9	Recruitment finished
16/LO/0124	182955	A study of the ReCor Paradise System in Clinical Hypertension	Yes, target number agreed	10/01/1900	10/01/1900	Yes a date was agreed	17/12/2019	11	24/01/2018	11	Recruitment finished
14/LO/1559	152866	Sorin Universal REgistry on Aortic Valve Replacement	Yes, target number agreed	20/01/1900	09/02/1900	Yes a date was agreed	01/09/2018	40	01/09/2018	40	Recruitment finished

15/NE/0167	171524	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation	Yes, target number agreed	06/01/1900	06/01/1900	Yes a date was agreed	25/11/2019	2	12/09/2018	2	Recruitment finished
15/LO/1641	180563	Global Clinical Study of Renal Denervation with the Symplicity Spyralâ„¸ multi-electrode renal denervation system in Patients with Uncontrolled Hypertension in the Absence of Antihypertensive Medications	Yes, target number agreed	05/01/1900	10/01/1900	Yes a date was agreed	01/11/2019	16	04/06/2018	16	Recruitment finished
15/LO/1163	181430	A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed on Regimens containing ABC/3TC	Yes, target number agreed	30/01/1900	30/01/1900	Yes a date was agreed	31/12/2017	22	30/03/2018	22	Recruitment finished
15/LO/1640	180561	Global Clinical Study of Renal Denervation with the Symplicity Spyralâ„¸ multi-electrode renal denervation system in patients with uncontrolled hypertension on standard medical therapy	Yes, target number agreed	05/01/1900	10/01/1900	Yes a date was agreed	31/12/2019	5	03/05/2018	5	Withdrawn by Host
15/LO/1487	172859	A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer	Yes, target number agreed	03/01/1900	03/01/1900	Yes a date was agreed	01/08/2018	3	24/01/2018	3	Recruitment finished
13/EE/0214	128290	A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects with Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial	Yes, target number agreed	01/01/1900	02/01/1900	Yes a date was agreed	14/02/2018	2	14/02/2018	2	Recruitment finished
10/H0801/67	145462	Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Risk Prostate Cancer: Feasibility Study	Yes, target number agreed	15/01/1900	15/01/1900	Yes a date was agreed	31/07/2018	4	11/05/2018	4	Recruitment finished
11/EE/0256		Multi-centre, open label, prospective, consecutive series registry database of BioPoly RS Partial Resurfacing Knee implant	Yes, target number agreed	10/01/1900	10/01/1900	Yes a date was agreed	31/12/2016	6	01/06/2018	6	Recruitment finished